[
    [
        {
            "time": "",
            "original_text": "辉瑞跌落榜首，罗氏首次登顶，4家中国药企上榜全球50强",
            "features": {
                "keywords": [
                    "辉瑞",
                    "罗氏",
                    "中国药企",
                    "全球50强"
                ],
                "sentiment_score": -0.2,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "辉瑞跌落榜首，罗氏首次登顶，4家中国药企上榜全球50强",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "中银创新医疗混合基金最新净值涨幅达1.51％",
            "features": {
                "keywords": [
                    "中银创新医疗",
                    "混合基金",
                    "净值涨幅"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "中银创新医疗混合基金最新净值涨幅达1.51％",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 3,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "【医药】疫情反复下重点关注检测行业和疫苗——兼论我们为什么看好吸入制剂赛道以及健康元发展前景",
            "features": {
                "keywords": [
                    "疫情",
                    "检测行业",
                    "疫苗",
                    "吸入制剂",
                    "健康元"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "检测",
                    "疫苗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【医药】疫情反复下重点关注检测行业和疫苗——兼论我们为什么看好吸入制剂赛道以及健康元发展前景",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        }
    ]
]